Multidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma
Authors:
- Peter Jianrui LiuPLPeter Jianrui Liu
- Harriet FergusonHFHarriet Ferguson
- Nikola GushterovNGNikola Gushterov
- Benedikt KesslerBKBenedikt Kessler
- Geoffrey LiuGLGeoffrey Liu
- Andreas HalnerAHAndreas Halner
- Luke HankeyLHLuke Hankey
- Iliyana KanevaIKIliyana Kaneva
- Mrunmayee DupalliwarMDMrunmayee Dupalliwar
- Junetha SyedJSJunetha Syed
- Emma MiEMEmma Mi
- Ella MiEMElla Mi
Preprint
- 31 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Lung cancer is the leading cause of cancer mortality worldwide with 70% diagnosed late stage despite low-dose computed tomography (LDCT) screening availability. We combined data-independent acquisition mass-spectrometry (DIA-MS) and proximity extension assay (PEA) with explainable artificial intelligence (XAI)-led machine learning (ML) for plasma-based biomarker discovery. From a 490 lung cancer and 124 matched-control cohort, ML models were trained to predict lung cancer achieving an AUROC of 0.91 [95% CI: 0.88–0.93] and 0.97 [95% CI: 0.92–0.98] in DIA-MS and PEA, respectively. XAI characterised networks of model-consistent features primarily related to infection and inflammatory responses. We then introduced a DNA-aptamer proteomics method and identified a cross-platform concordance panel, with performances of 0.88 [95% CI: 0.80–0.90] and 0.88 [95% CI: 0.81–0.95] in DIA-MS and PEA, respectively. This study demonstrates that combining multi-dimensional proteomics with XAI-ML can characterise robust biomarker signatures.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre studyClinical and Translational Medicine, 2025
- The benefits and pitfalls of machine learning for biomarker discoveryCell and tissue research, 2023
- Uptake of invitations to a lung health check offering low-dose CT lung cancer screening among an ethnically and socioeconomically diverse population at risk of lung cancer in the UK (SUMMIT): a prospective, longitudinal cohort studyThe Lancet Public Health, 2023
- Exact Shapley values for local and model-true explanations of decision tree ensemblesMachine Learning with Applications, 2022
- Novel Antibodies for the Simple and Efficient Enrichment of Native O-GlcNAc Modified PeptidesMolecular & Cellular Proteomics, 2021
- Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significanceCancer Treatment and Research Communications, 2021
- Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)Molecular Diagnosis & Therapy, 2019
- Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015JAMA Oncology, 2017
- Myoglobin plasma level related to muscle mass and fiber composition – a clinical marker of muscle wasting?Journal of Molecular Medicine, 2007
- The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancerClinical Immunology, 2006